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ABSTRACT 
OBJECTIVE: Older adults with Down Syndrome (DS) often have 
Alzheimer’s disease (AD) neuropathologies. While PET imaging studies of 
amyloid deposition (Aβ) have been associated with worse clinical 
prognosis and cognitive impairment, their relationships with cortical 
thickness remain unclear in people with DS. 
 
METHODS: In a sample of 44 DS adults who underwent cognitive 
assessments, [11C]-PiB PET and T1-MPRAGE, we used mixed effect 
models to evaluate the spatial relationships between Aβ binding with 
patterns of cortical thickness. Partial Spearman correlations were used to 
delineate the topography of local Aβ-associated cortical thinning.  
 
RESULTS: [11C]-PiB BPND was negatively associated with decreased 
cortical thickness. Locally, regional [11C]-PiB retention was negatively 
correlated with cortical thickness in widespread cortices, predominantly in 
temporo-parietal regions. 
 
CONCLUSION: Contrary to the prevailing evidence in established AD, we 
propose that our findings implicate Aβ in spatial patterns of atrophy that 
recapitulated the “cortical signature” of neurodegeneration in AD, 
conferring support to recent recommendations for earlier disease- 
interventions.  
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INTRODUCTION 
Down’s Syndrome (DS) is the most common neurodevelopmental disorder 
caused by the presence of trisomy 21 (1:800 live births). The extra copy 
of chromosome 21 is associated with a 4-5 fold overexpression of the 
amyloid precursor protein (APP) gene and increased accumulation of 
cerebral beta-amyloid (Aβ) deposition (Wiseman et al., 2015). The 
“amyloid cascade hypothesis” – the most widely accepted biomarker 
model of disease progression in AD – postulates that amyloidosis is the 
initiating event in the pathogenesis of dementia, triggering a self-
perpetuating cascade involving tau hyperphosphorylation, synaptic injury, 
downstream macroscopic brain atrophy, and ultimately clinical decline 
(Hardy, 2002).  
 
Convergent lines of evidence support a similar Aβ-induced pathogenic 
cascade in people with DS (Neale et al., 2018). Histopathological studies 
have observed a high prevalence of neuritic plaques and neurofibrillary 
tau tangles (NFTs), occurring as early as the 20s and in nearly all DS 
adults after the age of 40. The clinical and imaging phenotypes of DS also 
appear to show a similar spatiotemporal evolution to that seen in sporadic 
AD; people with DS develop cognitive decline in adulthood (Hithersay et 
al., 2017) and show patterns of  brain atrophy especially in the 
hippocampal regions and temporo-parietal cortices (Annus et al., 2017; 
Dickerson et al., 2009; Mullins et al., 2013; Teipel et al., 2004). This 
temporo-parietal atrophy in DS adults emerges in the presence of 
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cerebral amyloidosis as measured by elevated [11C]-PiB binding (Annus et 
al., 2017).  Such a pattern of atrophy is also similar to previous studies in 
AD, wherein cortical thinning has been proposed as a sensitive surrogate 
of disease progression and neurodegenerative changes in AD (Dickerson 
et al., 2009). 
 
Precisely how Aβ accumulation might lead to neurodegeneration, 
however, remains uncertain. Studies in the AD and cognitive impaired 
cohorts suggest that Aβ accumulation reaches an early plateau whereas 
atrophy is progressive (Jack et al., 2013), in turn meaning that the two 
phenomena are not correlated (Josephs et al., 2008). An advantage of 
studying DS, in contrast, is that the inevitability of Aβ accumulation 
means that one can study the influence of Aβ deposition to atrophy before 
cognitive decline has begun and with a range of severities of both 
phenomena. To this end, cortical thickness has been proposed and 
recognized as a sensitive  surrogate of neurodegeneration AD (Dickerson 
et al., 2009). 
 
 
To explore the pathological associations of Aβ and cortical thickness in 
DS, we performed a multi-modal imaging study involving [11C]-PiB 
imaging and structural MRI, and examined the extent to which regional 
Aβ maps onto cortical thickness in a DS cohort at various stages of 
amyloidosis (i.e. presence or absence of substantial Aβ burden) and 
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cognitive functioning (i.e. no evidence of acquired cognitive impairment 
versus age-related acquired cognitively impaired or demented). Our 
primary hypotheses were as follows: (a) increased Aβ is associated with 
decreased cortical thickness, and (b) this relationship would be stronger 
before the onset of objective cognitive decline. 
 
METHODS 
Study design and participants 
Forty-four participants with DS aged 25 – 65 volunteered to take part and 
successfully completed the neuropsychological assessments and imaging 
protocol of this study. Participants were identified via services for people 
with intellectual disabilities in England and Scotland, through the Down’s 
Syndrome Association or following responses to our website. All 
participants had previously received a clinical diagnosis of DS based on 
having the characteristic phenotype. The study was approved by the 
National Research Ethics Committee of East of England and the 
Administration of Radioactive Substances Advisory Committee. Written 
consent was obtained from all adults with DS with the capacity to 
consent. For participants lacking the capacity to consent, the procedures 
set out in the England and Wales Mental Capacity Act (2005) or the Adults 
with incapacity (Scotland Act), depending on place of residence, were 
followed. 
 
Clinical assessments 
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All participants were assessed for dementia using the Cambridge 
Examination for Mental Disorders of Older people with Down’s Syndrome 
and Others with Intellectual Disabilities (CAMDEX-DS) informant 
interview, designed for diagnosing dementia in this population (Roth et 
al., 1986). An experienced clinician (S.H.Z. or A.J.H.), who was blinded to 
the age of the participant and the PiB status, allocated each participant 
into the categories of (a) those without acquired cognitive impairment, 
(b) cognitive decline, (c) or dementia. Dementia was diagnosed in 
accordance with the International Classification of Diseases-10 (ICD-10) 
criteria for dementia. The diagnosis of “cognitive decline” was given to 
participants with informant reported evidence of functional decline in one 
or more cognitive domains without fulfilling the full ICD-10 criteria for 
dementia. 
 
Imaging protocol 
Structural MRI 
The T1-MPRAGE data were processed using Freesurfer (v5.3, available 
from https://surfer.nmr.mgh.harvard.edu) to estimate cortical thickness 
in 34 ROIs per hemisphere, based on the Desikan-Killiany parcellation 
scheme (Desikan et al., 2006). The technical procedures for surface 
reconstruction and quantification of cortical thickness have been 
described previously (Fischl and Dale, 2000). Briefly, the process involved 
automated non-uniformity bias correction, skull stripping, segmentation 
of the white matter and the boundary between the white and grey 
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matter. Segmented and skull-stripped data of all partic- ipants were 
visually inspected for parcelation errors, and topolog- ical defects in the 
gray/white matter boundary were manually corrected. The gray/white 
boundary served as a starting point for a deformable surface algorithm to 
compute the gray/white and pial surfaces, from which cortical thickness is 
calculated as the closest distance from the gray/white matter boundary to 
the pial surface at each vertex on the tessellated surface. In addition, 
PetSurfer was used to segment additional regions, such as the cerebral 
CSF, pons, skull and air cavities to facilitate partial volume correction of 
PET data (Greve et al., 2014). 
 
[11C]-PiB PET imaging 
[11C]-PiB data were acquired in three-dimensional (3D) mode on a GE 
Advance scanner. Before [11C]-PiB injection, a 15-minute transmission 
scan using rotating 68Ge rod sources was acquired to correct for photon 
attenuation. [11C]-PiB was produced with high radiochemical purity 
(>95%) and specific activity (>150 GBq/umol). [11C]-PiB was injected as 
a bolus (median= 545 MBq, interquartile range = 465-576MBq) through 
an antecubital venous catheter, and data were acquired for 90 min after 
injection in 58 frames (18 x 5, 6 x 15 seconds, 10 x 30 seconds, 7 x 1 
minute, 4 x 2.5 minutes, and 13 x 5 minutes). For each frame, sono` 
data were reconstructed using the PROMIS 3D filtered back projection 
algorithm into a 128 x 128 x 35 image array with a voxel size of 2.34 x 
2.34 x 4.25mm3. Corrections were applied for random coincidences, dead 
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time, normalization, scatter, attenuation and sensitivity. The dynamic PET 
images were realigned with statistical parametric mapping (SPM) and 
averaged. The resultant mean images were co-registered to their 
corresponding bias-corrected magnetisation-prepared, rapid gradient-
echo MRI (MPRAGE) volume. Consistent with previous studies (Hanseeuw 
et al., 2017; LaPoint et al., 2017) , the geometric transfer matrix (GTM) 
technique was used to derive partial-volume corrected ROIs. 
Subsequently, kinetic modelling was performed using the two-stage 
Multilinear Reference Tissue Model (MRTM2) implemented in PetSurfer 
(Ichise et al., 2003) to estimate non-displaceable binding potential 
(BPND), using the cerebellum as the reference region. Classifications of Aβ 
“positivity” and “negativity” were assigned based on elevated binding in 
the striatum, which has been shown to clearly separate the positive and 
negative groups in our previous work (Annus et al., 2016) as well as 
others (Handen et al., 2012; Lao et al., 2017). 
 
Statistical analyses 
All statistical analyses were performed in MATLAB 2017A and the R 
statistical package. The specific analyses are described below. To 
determine the topographical covariance of Aβ and cortical thickness 
across the cortex, we first examined correlations between the inter-
regional [11C]-PiB BPND and cortical thickness. To account for the inter-
dependency resulting from repeated measurements per participant (i.e. 
68 ROIs), mixed effect models were used to examine the relationship 
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between all brain regions combined across [11C]-PiB BPND and cortical 
thickness datasets, treating participants and lobes as random factors. 
Next, to elucidate the local associations of Aβ pathology with cortical 
thinning, we pursued an unbiased approach and investigated Spearman 
partial correlations between Aβ binding and cortical thickness within the 
same ROI while adjusting for age. A Benjamini-Hochberg False Discovery 
Rate adjusted (FDR) significance level of p < 0.05 was used to correct for 
multiple comparisons.  
 
RESULTS 
Demographics and clinical features 
Brief demographics of the cohort are shown in Table 1.  
 
Mixed effects modelling of relationship between Aβ and cortical 
thickness  
Across the total sample of DS adults, our mixed effect models indicated a 
highly significant negative relationship between Aβ binding and cortical 
thickness [Estimate = -1.2 ± 0.03, t = -39.5], χ2 (1), p < 0.001] (Figure 
1A). The statistical significance of this association was retained after we 
repeated the mixed effect models separately for Aβ+ [Estimate = -0.8 ± 
0.04, t = -20.7], χ2 (1), p < 0.001] and Aβ- groups [Estimate = -1.3 ± 
0.04, t = -32.9], χ2 (1), p < 0.001] (Figure 1B-C). To further evaluate 
the consistency of associations across disease stages, we evaluated two 
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separate mixed effect models for DS adults with no evidence of acquired 
cognitive impairment, and DS adults judged to have objective cognitive 
impairment or dementia. While increased Aβ binding was significantly 
associated with a thinner cortex within each cognitive subgroup, the 
associations were notably stronger amongst those without acquired 
cognitive impairment [Estimate = -1.2 ± 0.03, t = -34.0], p < 0.001] 
compared to the group with cognitive impairment or dementia [Estimate 
= -0.8 ± 0.04, t = -17.0], p < 0.001]. 
 
Topography of local-to-local associations of Aβ and cortical 
thickness 
Our next objective was to delineate the topography of local Aβ-associated 
thinner cortices in DS. We investigated Spearman partial correlations 
between [11C]-PiB BPND and cortical thickness in the same ROI while 
adjusting for age and correction for multiple comparisons (FDR), and 
found widespread extent of highly significant inverse relationships 
between increased Aβ binding and cortical thickness. The peak 
correlations were predominantly localized within temporo-parietal (r ~ -
0.4 – -0.7, FDR adjusted p < 0.05). The spatial pattern of Aβ-associated 
cortical thickness decrease is represented as a heat map on the Desikan-
Kiliany template, where the color gradient depicts the strength of the 
negative correlations (Figure 2). To explore the potential impact of age on 
these associations, we repeated the analyses without controlling for age, 
and obtained highly similar distributions of local associations. The 5 ROIs 
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that did not retain significance were the left entorhinal, left lateral 
occipital, left lateral orbitofrontal, left paracentral and left pars opercularis 
cortices.  
 
Associations of Aβ and cortical thinning across levels of 
amyloidosis and cognitive impairment 
 
Local associations stratified by striatal-Aβ status 
Next, we inquired whether striatal-Aβ status may modulate the local 
relationship between Aβ and cortical thickness. A one-way analysis of 
covariance (ANCOVA), treating the Aβ+ and Aβ- groups as a factor and 
cortical thickness as a covariate, indicated stronger associations amongst 
the striatal-Aβ- group in predominantly frontal regions (FDR adjusted p < 
0.05). These interaction analyses were further corroborated by our 
within-subgroup correlational analyses, which revealed markedly distinct 
maps of Aβ-associated cortical thinning in both subgroups (Figure 3). 
While the striatal-Aβ- group showed significant Aβ-associated cortical 
thinning in widespread regions involving the frontal and parietal cortices, 
the peak correlations were mostly restricted to the temporal cortices 
amongst the striatal-Aβ+ DS adults (FDR adjusted p < 0.05). To capture 
subtle Aβ associations with cortical thinning amongst the striatal-Aβ+ DS 
adults, we also reported the findings at uncorrected p < 0.05 in 
Supplementary Figure 1, where there was a relatively marked absence of 
Aβ associations in the frontal lobe. 
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Local associations stratified by cognitive status 
To determine whether Aβ was associated with cortical thickness across 
varying degrees of acquired cognitive impairment in DS, we repeated 
these local correlations separately amongst DS adults without acquired 
cognitive impairment (n = 31) and DS adults with cognitive decline or 
dementia (n = 13). Within the DS group with no acquired cognitive 
impairment, we observed a widespread pattern of significant correlations 
in a pattern that is largely consistent with that of the total sample (FDR 
adjusted p < 0.05). In contrast, correlations between Aβ and cortical 
thickness did not survive FDR correction, although this was expected 
considering the smaller sample size (n = 13).  
 
DISCUSSION 
In this present study, we mapped the topographic distribution of Aβ 
binding onto patterns of cortical thickness in DS adults, and present the 
first evidence that both phenomena are tightly coupled in a spatial 
pattern consistent with the known “cortical signature” of 
neurodegeneration in AD. In accordance with our hypothesis, our findings 
further suggest that the coupling between Aβ and a thinner cortex is more 
pronounced in the earlier stages of disease, particularly in DS adults with 
minimal Aβ burden before the onset of acquired cognitive impairment in 
DS. Collectively, our findings reinforce the notion that early intervention, 
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particularly with the aim of targeting Aβ, may have the most therapeutic 
potential during the asymptomatic stages of DS and AD. 
 
While it is well-established that Aβ represents the initiating pathogenic 
factor in AD, its precise relationships with downstream neurodegeneration 
and clinical severity have been controversial (Jagust, 2016). Converging 
data from post-mortem and PET imaging studies have indicated that the 
regional distribution and severity of Aβ plaques do not correspond with 
brain atrophy or clinical severity (Chetelat et al., 2010; Erten-Lyons et al., 
2013; Josephs et al., 2008). The relevance of the “amyloid cascade” 
model has also been challenged by the recent spate of failures in Phase 
III anti-Aβ clinical trials. However, researchers have attempted to 
reconcile these inconsistencies by citing the disparity between the slow 
progression of Aβ accumulation and the accelerating trajectories of 
neurodegeneration (Jack et al., 2013). In this vein, a clearer picture of 
Aβ-associated atrophy emerges in cohorts that are comprised of 
cognitively normal elderly and individuals in the early stages of AD 
(Chetelat et al., 2010; Doré et al., 2013; Jack et al., 2009). For instance, 
accelerated rates of brain atrophy have been reported in cognitively 
normal elderly with elevated Aβ burden (Chetelat et al., 2012), consistent 
with evidence of strong associations between elevated Aβ burden and 
decreased cortical thickness (Doré et al., 2013). Several aspects of our 
data therefore are consistent with the notion that the association of Aβ 
with neurodegeneration is particularly salient during the prodromal stages 
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of AD in that the coupling of Aβ accumulation with a thinner cortex was 
stronger in (a) DS adults without acquired cognitive impairment and (b) 
in DS adults who had not reached the threshold to be classified as Aβ+. 
 
After establishing that Aβ accumulation is associated with a thinner cortex 
in DS, our local correlations sought to delineate the topographical 
distribution of Aβ-associated atrophy. In the total sample of DS, we found 
a widespread pattern of negative correlations that peaked within the 
temporo-parietal cortices, mirroring the “cortical signature” of atrophy in 
AD (Dickerson et al., 2009). Based on the remarkable spatial overlap 
between our Aβ-atrophy map and that of the AD “cortical signature”, it is 
conceivable that the topographic distribution of Aβ-associated atrophy 
may reflect the regional susceptibility to the neurotoxicity of Aβ. 
Intriguingly, the spatial distribution of our peak correlations is also very 
similar to that of another study reporting strong associations of Aβ and 
cortical thinning in healthy controls especially within the bilateral 
precuneus and medial temporal regions (Doré et al., 2013), both of which 
have been shown to undergo atrophy in DS adults (Mullins et al., 2013) 
with elevated burden of Aβ (Annus et al., 2017; Lao et al., 2017).  
 
Another question with important implications for the optimisation of 
clinical trials is whether the coupling between Aβ and cortical thickness is 
consistent across varying degrees of disease severity over the course of 
AD. In keeping with our hypothesis, we observed extensive Aβ-related 
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atrophy after the correlational analyses were repeated within the 
subgroup of DS adults who were cognitively stable, suggesting an early 
process of Aβ-related neurodegeneration preceding the onset of cognitive 
impairment. This finding was also supported by our interaction analyses 
which indicated stronger associations amongst the striatal-Aβ-DS, 
particularly in the frontal cortices. While this could have been attributed 
to the smaller sample size of the striatal-Aβ+ group, subjecting the 
correlational tests to a more liberal threshold of uncorrected p < 0.05 
only yielded a single association in the right pars opercularis (i.e. all other 
associations in the frontal lobe remained insignificant amongst the 
striatal-Aβ+ group (Supplementary Figure 1). Relative to the striatal-Aβ- 
group, the weaker associations within the frontal lobe amongst the 
striatal-Aβ+ group could be interpreted in light of the known propagation 
of Aβ (Thal et al., 2014). In other words, DS adults with elevated Aβ 
burden are most likely further down the pathway to AD, and consequently 
Aβ accumulation in the frontal lobe may have begun to plateau (Thal et 
al., 2014). In future longitudinal studies, it would be of clinical interest to 
examine whether the spatiotemporal trajectories of cortical thinning are 
distinct in Aβ subgroups.  
 
Despite the prominent correlations observed herein and in other studies 
(Chetelat et al., 2010; Doré et al., 2013; Jack et al., 2009), the precise 
mechanisms by which Aβ leads to downstream brain atrophy remains 
elusive. It has been shown that Aβ oligomers could directly result in 
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synaptic injury and cell loss (Walsh and Selkoe, 2007). Such a mechanism 
would entail a spatial correspondence between the presence of early Aβ 
deposition and neurodegeneration, as evidenced by our findings of 
prominent local associations in regions typically associated with abundant 
deposits of Aβ (i.e. frontal and parietal cortices (Arnold et al., 1991; Rowe 
et al., 2007)).  
 
The coupling of Aβ with cortical thinning in several regions of the medial 
temporal lobe - despite being a later site of Aβ deposition – also merit 
further discussion (i.e. fusiform, entorhinal, and inferior temporal cortices 
amongst others). Given that these regions are amongst the earliest sites 
of abnormal tau aggregation in the disease course of AD (Braak and 
Braak, 1991), it is plausible that Aβ-associated atrophy – particularly in 
the medial temporal cortex where Aβ is not commonly observed in the 
earlier stages of AD – may be mediated by tau hyperphosphorylation, a 
phenomenon which may have already begun in our striatal-Aβ+ 
individuals (Supplementary Figure 1). Moving forward, PET investigations 
of [18F]-AV1451 for tau and [11C]-PiB imaging in DS cohorts will no doubt 
clarify this question in future and clarify the relative contributions of tau 
and Aβ to the disease progression of DS (i.e. The Alzheimer’s Biomarkers 
Consortium – Down Syndrome (ABC-DS) that encompasses the NIAD 
study; https://niad-project.org/) and the ADDS (Alzheimer’s Disease in 
Downs Syndrome; ; https://www.nia.nih.gov/research/abc-ds). 
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The widespread prevalence and premature comorbidity of AD pathology in 
DS presents valuable opportunities to study the early implications of AD 
pathogenesis within a naturally enriched population. Contrary to the 
consensus that Aβ is not associated with downstream neurodegeneration 
in established AD, our present findings in DS showed that the coupling 
between Aβ deposition and cortical thinning may be more pronounced in 
the earliest stages of dementia. Furthermore, we showed that Aβ-
associated atrophy in DS manifests even in the absence of acquired 
cognitive impairment or substantial Aβ burden. Moving forward, 
elucidating the deleterious implications of amyloid-β burden and 
longitudinal rates of brain atrophy would be of high importance to (a) 
improve our understanding of the underlying neuropathological substrates 
that drive spatial patterns of downstream neurodegeneration, (b) aid 
development of new disease-modification against AD pathologies, and (c) 
support the utility of amyloid PET imaging to track disease progression 
and monitor treatment outcomes.  
 
A potential caveat associated with imaging studies of developmental 
conditions is the uncertainty over Freesurfer’s ability to accurately 
measure cortical thickness due to inherent differences in brain 
morphology compared to the general population. For instance, reduced 
signal contrast between the grey and white matter – a phenomenon 
recently reported in DS (Bletsch et al., 2018) – may hinder reliability of in 
vivo estimates of cortical thickness. While previous studies have used 
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manual tracing on a priori selected brain regions, they were limited by the 
labour intensive and operator-dependent procedures, both of which are 
challenges that may hinder their adoption as imaging biomarkers in large 
scale clinical trials for DS. In addition, only predefined regions may be 
investigated using a manual tracing approach. Cortical thickness 
measurements from Freesurfer have also been validated against 
histological data and other manual measurements (Cardinale et al., 2014; 
Fischl and Dale, 2000), and has been widely applied to interrogate cortical 
changes in the DS neuroimaging literature (see Neale et al., 2018 for a 
systematic review). In future, it will be essential to validate these 
conclusions using histological data as existing post-mortem studies in DS 
are scarce. 
 
Finally, ageing presents another caveat in the interpretation of the 
relationships between Aβ accumulation and cortical thinning. An early 
process of accelerated age-related cortical thinning has been previously 
described in DS (Cole et al., 2017), supported by other studies reporting 
prominent localisation of age-related atrophy in frontal association 
cortices (Romano et al., 2016; Teipel et al., 2004). In a similar vein, our 
previous work has shown that the spatial extent of Aβ accumulation 
increases with age (Annus et al., 2016). In order to guard against the 
possibility that both Aβ accumulation and cortical thinning are merely 
progressing along a common age-related pathway, we compared the 
spatial maps of Aβ-associated atrophy, with and without accounting for 
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age, and found two largely similar spatial distributions (i.e. Only 5/45 
ROIs did not retain statistical significance after correcting for age), 
supporting the idea that Aβ may exert its deleterious effects on cortical 
thickness over and above an accelerated ageing process.  
 
Finally, our findings are consistent with a recent case-report of a rare DS 
patient with partial trisomy of chromosome 21 (PT21) who lacked 
triplication of APP (Doran et al., 2017). Intriguingly, the patient showed 
(i) relatively stable cognitive performances over time and had no signs of 
dementia on neurological examinations; (ii) lower [11C]-PiB binding than 
healthy controls; (iii) and histological examinations revealed only a single 
neuritic plaque.  Interpreted in light of our strong associations between 
Aβ and cortical thinning, these findings further argue for an obligatory 
role of Aβ in driving the AD disease cascade in people with DS. 
Nevertheless, we cannot be certain as to what extent the proposed role of 
Aβ in the causation of neurodegeneration and AD in people with DS can 
be generalised to the typically developing population. However, if such a 
relationship had not been found in DS, where Aβ levels are markedly 
increased, that would have been a significant challenge to the amyloid 
cascade hypothesis.  The fact this inverse relationship between Aβ and 
cortical thickness has been found provides further support for this 
hypothesis.  
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FIGURE LEGENDS 
 
Figure 1. Topographical covariance of Aβ and decreased cortical 
thickness. The scatter plots depict the associations between Aβ and 
cortical thickness measures across (a) total sample, (b) DS striatal-Aβ+ 
adults, and (c) DS striatal-Aβ-adults. Each data point represents a single 
cortical region of interest from a single subject, parcellated with the 
Desikan-Killiany template. 
 
Figure 2. The topographical distribution of local Aβ-associated 
atrophy in the total sample of DS. These regions showed significantly 
negative correlations between [11C]-PiB BPND and cortical thickness (FDR 
adjusted p < 0.05, adjusted for age). The colors represent the strength of 
the negative correlations, increasing in magnitude from dark blue to cyan.  
Abbreviations: Lh = Left hemisphere; Rh = Right hemisphere; DS = 
Down Syndrome. 
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Figure 3. Topographic distributions of Aβ-associated atrophy 
stratified by Aβ status. Amongst the Aβ- DS adults, local Aβ deposition 
was significantly associated with decreased cortical thickness in 
widespread regions predominantly fronto-parietal cortices whereas the 
spatial extent of associations was more restricted to the temporal cortices 
and precuneus in the Aβ+ DS adults. Abbreviations: Lh = Left 
hemisphere; Rh = Right hemisphere; DS = Down Syndrome. 
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Table 1. Brief demographics and cognitive characteristic of the study sample.  
 
 Adults with Down’s 
Syndrome (n=44) 
Age, years (± SD) 41.95 ± 8.7 
Female 54.55% 
CAMCOG score (± SD) 75.22 ± 19.62 
Elevated striatal [11C]-PiB binding 
(absent/present) 
18:26 
Acquired cognitive impairment or dementia 
(%) 
30% 
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HIGHLIGHTS 
1. In a sample of adults with Down’s Syndrome (DS), amyloid burden 
(Aβ) was strongly associated with cortical thinning. 
2. The topography of Aβ-associated atrophy is similar to the cortical 
signature of atrophy in Alzheimer’s disease. 
3. These findings further implicate Aβ in the pathophysiology of DS. 
4. Further longitudinal studies are necessary to clarify the extent to 
which baseline Aβ imaging could predict downstream severity of 
brain atrophy in DS.  
